American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, D. C., 1994.
Andreasen, N. C., Carpenter, W. T. Jr., Kane, J. M. et al.: Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry, 162: 441-449, 2005.
Awad, A. G., Voruganti, L. N., Heslegrave, R. J.: A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual. Life Res., 6: 21-26, 1997.
Bilder, R. M., Goldman, R. S., Volavka, J. et al.: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 159: 1018-1028, 2002.
Breier, A., Schreiber, J. L., Dyer, J. et al.: National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch. Gen. Psychiatry, 48: 239-246, 1991.